Hongmei is a seasoned leader in clinical pharmacology, pharmacometrics, and DMPK, with a proven track record of delivering efficient clinical pharmacology and DMPK programs that fully meet regulatory requirements. She brings over 15 years of experience in drug development, spanning discovery, clinical development, and commercialization/post-marketing, across diverse therapeutic areas and modalities, including small molecules, peptides, and antibody-drug conjugates (ADCs). Hongmei has led multiple successful submissions across major health authorities, including the FDA, EMA, PMDA, Health Canada, and TGA. A leader in the field, her work has been published in over 40 peer-reviewed articles and presented at national conferences.